The GH-IGF system in amyotrophic lateral sclerosis: Correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features

M. T. Pellecchia, R. Pivonello, M. R. Monsurrò, F. Trojsi, K. Longo, G. Piccirillo, C. Pivonello, M. Rocco, C. Di Somma, A. Colao, G. Tedeschi, P. Barone

Research output: Contribution to journalArticlepeer-review

Abstract

Background and purpose: The growth hormone (GH) and insulin-like growth factor (IGF) system may be involved in neurodegenerative processes, and some abnormalities have been reported in amyotrophic lateral sclerosis (ALS). Our aim was to investigate the GH-IGF axis in patients with ALS and evaluate correlations between this endocrine system and clinical features. Methods: Serum levels of GH, IGF-I, IGF-II, insulin, IGF-binding protein 1 (IGF-BP1), and IGF-binding protein 3 (IGF-BP3) were measured in 25 patients with ALS and 25 age-, gender-, and BMI-matched healthy controls. A GHRH plus arginine test was performed in patients and controls. Clinical status of patients was evaluated with the ALS Functional Rating Scale - Revised (ALSFRS-R) and upper motor neuron (UMN) score. Results: GHRH plus arginine test showed GH deficiency (GHD) in 13 (52%) patients with ALS; severe GHD was found in 6 (24%) and partial GHD in 7 (28%) patients. IGF-I levels were significantly higher in patients with ALS than in healthy controls (182.9 ± 90.8 vs. 139.4 ± 58.1 ng/ml; P = 0.015). IGF-I levels were higher in patients with ALS with UMN score >10 than those with UMN score

Original languageEnglish
Pages (from-to)666-671
Number of pages6
JournalEuropean Journal of Neurology
Volume17
Issue number5
DOIs
Publication statusPublished - May 2010

Keywords

  • Amyotrophic lateral sclerosis
  • Growth hormone
  • Insulin-like growth factor-I
  • Insulin-like growth factor-II

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'The GH-IGF system in amyotrophic lateral sclerosis: Correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features'. Together they form a unique fingerprint.

Cite this